טוען...
Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
BACKGROUND: Lymphoma is a common cancer in dogs. While most dogs receiving chemotherapy experience remission, very few are cured, and median survival times are generally in the 12-month range. Novel approaches to treatment are unquestionably needed. The Inhibitor of Apoptosis Protein (IAP) family me...
שמור ב:
| הוצא לאור ב: | BMC Vet Res |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7092583/ https://ncbi.nlm.nih.gov/pubmed/32209084 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12917-020-02317-3 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|